Physician profile
William J Wickwire
NPI 1699779660
$5,293.60
in general payments reported to CMS, 2019-2025
31 companies · $585 in 2025
The $585 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,322 · 2020: $112 · 2021: $80.35 · 2022: $691 · 2023: $1,408 · 2024: $1,095 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,073 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,072.55 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $633.55 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $622.08 | 2023-2025 | Libtayo, Dupixent |
| Genzyme Corporation | $522.48 | 2019-2025 | |
| Abbvie INC. | $516.43 | 2019-2023 | Skyrizi |
| Dermavant Sciences, INC. | $334.18 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $328.14 | 2022-2025 | Tremfya, Simponi, Stelara |
| Incyte Corporation | $270.49 | 2022-2025 | Opzelura |
| Ucb, INC. | $195.90 | 2019-2024 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $185.29 | 2019-2025 | |
| Lilly USA, LLC | $184.56 | 2019-2025 | Ebglyss, Taltz |
| Leo Pharma INC. | $182.80 | 2022-2025 | Anzupgo, Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $179.54 | 2019 | |
| Amgen INC. | $178.48 | 2023-2024 | Otezla |
| Celgene Corporation | $178.39 | 2019 | |
| Fresenius Kabi USA, LLC | $118.35 | 2023 | Idacio |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $105.41 | 2019-2025 | Aklief |
| Sun Pharmaceutical Industries INC. | $91.19 | 2019-2024 | Blu-U, Odomzo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.25 | 2023-2024 | Spevigo |
| Genentech USA, INC. | $56.73 | 2019-2023 | Xolair |
| Botanix Sb INC | $52.93 | 2025 | Sofdra |
| Biofrontera INC. | $45.40 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| E.R. Squibb & Sons, L.L.C. | $45.08 | 2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $35.98 | 2023 | |
| Organon LLC | $28.22 | 2025 | Vtama |
| Krystal Biotech INC | $25.34 | 2024 | Vyjuvek |
| Revance Therapeutics, INC. | $23.78 | 2025 | Daxxify |
| Mayne Pharma Commercial LLC | $22.57 | 2019 | |
| Allergan, INC. | $20.16 | 2021 | |
| Dermira, INC. | $18.77 | 2019 | |
| Dusa Pharmaceuticals, INC. | $16.43 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $15.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Wickwire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.